Centessa (CNTA) insider plans 12,000-share sale worth $168k – Form 144

Centessa Pharmaceuticals plc (NASDAQ: CNTA) has submitted a Form 144 notifying the SEC of a proposed sale of 12,000 common shares by an insider through UBS Financial Services on 24 June 2025.

Rhea-AI Filing Summary

Centessa Pharmaceuticals plc (NASDAQ: CNTA) has submitted a Form 144 notifying the SEC of a proposed sale of 12,000 common shares by an insider through UBS Financial Services on 24 June 2025. The estimated aggregate market value is $168,218.40, implying a per-share price of roughly $14.02. The filing states that 133,618,774 shares are outstanding, meaning the planned sale represents less than 0.01 % of total shares. The seller acquired the shares the same day via a cash-settled stock-option exercise.

The insider previously sold a combined 6,000 shares over the past three months for total proceeds of $84,012.01. No additional operational or financial data were disclosed, and the signatory affirms awareness of no undisclosed material adverse information. Given the modest size relative to the float and the routine nature of Form 144 notices, the event is unlikely to materially affect Centessa’s fundamentals or valuation.

Insights

Corporate Governance Analyst

TL;DR: Minor insider sale; negligible ownership impact; neutral market effect.

The Form 144 reveals an insider’s intent to sell 12,000 CNTA shares, equal to roughly 0.009 % of the company’s outstanding equity. Past 90-day sales totaled another 6,000 shares, suggesting a gradual, modest liquidation pattern rather than aggressive dumping. Because the shares were obtained via option exercise on the same day, the transaction appears to be routine diversification or tax-related liquidity. No 10b5-1 plan date was disclosed, but the attestation of no undisclosed adverse information mitigates governance concerns. Overall, the filing is informational with neutral to immaterial financial impact for investors.

FAQ

What SEC document did Centessa (CNTA) file?

Form 144—a notice of proposed insider sale of restricted or control securities.

How many CNTA shares are planned for sale?

The insider intends to sell 12,000 common shares.

What is the estimated value of the planned insider sale?

Approximately $168,218.40, based on the filing’s market value estimate.

When is the approximate sale date for these shares?

The filing lists 24 June 2025 as the expected sale date.

How significant is the sale relative to shares outstanding?

It equals less than 0.01 % of the 133,618,774 shares outstanding, a negligible amount.

Has the insider sold CNTA stock recently?

Yes; over the past 3 months the same insider sold 6,000 shares for gross proceeds of $84,012.01.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2025 - 04:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001862050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Centessa Pharmaceuticals plc
SEC File Number	001-40445
Address of Issuer	3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE UNITED KINGDOM WA14 2DT
Phone	44 7391 789784
Name of Person for Whose Account the Securities are To Be Sold	HUSSAIN IQBAL J
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services Inc. 11 Madison Ave 4th Floor New York NY 10010	12000	168218.40	133618774	06/24/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/24/2025	Exercise of Stock Options	Issuer			12000	06/24/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM, CHESHIRE X0 WA14 2DT	Common	04/25/2025	3609	50526.36
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM X0 X0 WA142DT	Common	04/28/2025	2080	29131.65
Iqbal Hussain 3RD FLOOR 1 ASHLEY ROAD ALTRINCHAM X0 X0 WA142DT	Common	05/01/2025	311	4354.00

144: Remarks and Signature

Remarks	The transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan
Date of Notice	06/24/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/14/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Iqbal Hussain
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)